Impact of extrafine single-inhaler triple therapy on treatment adherence after 6 months of treatment in asthmatics: a real-world view from Germany

Background Randomized controlled trials (RCTs) showed significant clinical benefits of extrafine single-inhaler triple therapy (efSITT) consisting of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G; 87/5/9 µg). The study population in the RCTs comprised asthma patients not adequately controlled on LABA and medium- or high-dose ICS, and who experienced≥1 asthma exacerbation in the previous year. The impact of efSITT on treatment adherence in asthmatics in a real-world setting is unknown.